Literature DB >> 11353575

Aldosterone antagonists in the treatment of hypertension and target organ damage.

S Rajagopalan1, B Pitt.   

Abstract

Mineralocorticoids mediate a number of effects besides regulation of fluid and electrolyte balance. Recent evidence has revealed several nontraditional roles, sites of synthesis, and action for these steroids. Aldosterone, the principal mineralocorticoid in humans, appears to be synthesized in physiologically relevant amounts in both the heart and the vasculature, and plays an important role in vessel wall and myocardial remodeling. The genomic effects of aldosterone are mediated through activation of the classic mineralocorticoid receptor, whereas rapid nongenomic effects seem to involve a distinct receptor and result in activation of multiple downstream signaling pathways. Recently, several lines of evidence seem to suggest an important interaction between the nitric oxide and the aldosterone pathway in the adrenal gland and vasculature. The evolution of selective aldosterone receptor antagonists will help us understand the role that mineralocorticoids play in the pathogenesis of hypertension, heart failure, and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11353575     DOI: 10.1007/s11906-001-0046-2

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  53 in total

1.  Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators.

Authors:  F Zannad; F Alla; B Dousset; A Perez; B Pitt
Journal:  Circulation       Date:  2000-11-28       Impact factor: 29.690

2.  Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.

Authors:  N J Brown; K S Kim; Y Q Chen; L S Blevins; J H Nadeau; S G Meranze; D E Vaughan
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

3.  The role of nitric oxide in the regulation of aldosterone synthesis by adrenal glomerulosa cells.

Authors:  R Natarajan; L Lanting; W Bai; E L Bravo; J Nadler
Journal:  J Steroid Biochem Mol Biol       Date:  1997-04       Impact factor: 4.292

Review 4.  Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance.

Authors:  J W Funder
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

5.  Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation.

Authors:  J S Silvestre; V Robert; C Heymes; B Aupetit-Faisant; C Mouas; J M Moalic; B Swynghedauw; C Delcayre
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

6.  Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.

Authors:  R Rocha; P N Chander; K Khanna; A Zuckerman; C T Stier
Journal:  Hypertension       Date:  1998-01       Impact factor: 10.190

Review 7.  Specific nongenomic actions of aldosterone.

Authors:  E Falkenstein; M Christ; M Feuring; M Wehling
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

8.  Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.

Authors:  Y Sun; A Ratajska; G Zhou; K T Weber
Journal:  J Lab Clin Med       Date:  1993-10

9.  Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta.

Authors:  U Ikeda; T Kanbe; I Nakayama; Y Kawahara; M Yokoyama; K Shimada
Journal:  Eur J Pharmacol       Date:  1995-07-18       Impact factor: 4.432

10.  Production of aldosterone in isolated rat blood vessels.

Authors:  Y Takeda; I Miyamori; T Yoneda; K Iki; H Hatakeyama; I A Blair; F Y Hsieh; R Takeda
Journal:  Hypertension       Date:  1995-02       Impact factor: 10.190

View more
  3 in total

Review 1.  Mineralocorticoid receptor antagonists and hypertension: is there a rationale?

Authors:  Olga Gumieniak; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

Review 2.  Aldosterone and aldosterone antagonism in systemic hypertension.

Authors:  William H Frishman; Charles T Stier
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

Review 3.  The use of aldosterone receptor blockers in the treatment of hypertension.

Authors:  Myron H Weinberger
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-11       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.